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Purpose. To describe the use of intravitreal ranibizumab for choroidal neovascular membrane (CNVM) secondary to Vogt-
Koyanagi-Harada (VKH) syndrome. Methods. Interventional case report. Results. A 50-year-old woman presented with
conjunctival injection and bilateral eye pain. Vision was 20/400 and 20/80 in the right and left eyes, respectively. Bilateral iritis,
vitritis, and choroidal thickening were evident. Exudative retinal detachment was present in the left eye. Corticosteroid treatment
improved vision to 20/40 bilaterally. Methotrexate (MTX) was initiated and vision remained stable for 3 months. After a 5-month
losstofollow-up,visioninthelefteyedecreasedtoﬁngercounting(CF)andaparafovealCNVMwasidentiﬁed.After3intravitreal
ranibizumab injections, vision improved to 20/40. Twelve months later, despite inﬂammation control, vision decrease to CF due
to recurrent CNVM. A fourth ranibizumab injection was given. Twenty months later, best-corrected vision was 20/400, and an
inactive CNVM was present in the left eye. Conclusion. After initial CNVM regression and visual acuity improvement due to
ranibizumab, the CNVM recurred and became refractory to treatment. Despite control of inﬂammation and neovascularization,
VKH chronicity lead to permanent vision loss in our patient. A combinational treatment approach may be required in such
patients.
1.Introduction
Vogt-Koyanagi-Harada syndrome (VKH), an autoimmune
reaction against melanocytes [1], is characterized by
granulomatous panuveitis, exudative retinal detachments
(RD), subretinal ﬁbrosis, choroidal neovascular membrane
(CNVM) formation, and extraocular manifestations [2].
CNVMisfoundin2–15%ofVKHpatients[3].Wereporton
VKH-associated subfoveal CNVM treated with intravitreal
ranibizumab.
2.CaseReport
A 50-year-old Hispanic woman presented with headaches
and conjunctival injection for 14 days, and blurry vision
with bilateral eye pain for 6 days. Vision was 20/400 in the
right eye and 20/80 in the left eye. Anterior segment showed
bilateral iritis. Vitritis was present. B-scan revealed choroidal
thickening. Fluorescein angiography (FA) and ocular coher-
ence tomography (OCT) showed subretinal ﬂuid consistent
with exudative RD (Figure 1; left eye). Lumbar puncture was
normal.
Diagnosis of VKH was established and ocular inﬂam-
mation was initially treated with topical and systemic
corticosteroids. After 14 days, inﬂammation subsided and
vision improved to 20/40 in both eyes. Ten weeks later,
because of morbidity associated with prednisone use and
the chronicity of VKH, we initiated methotrexate (MTX)
treatment. Visual acuity remained stable for 3 months. After
a 5-month loss to follow-up (without immunosuppressive
treatment for the last 2 months), the patient returned with
recurred inﬂammation, 20/25 vision in the right eye, and
ﬁnger counting (CF) vision in the left eye because of a
parafoveal CNVM with mild intraretinal ﬂuid (Figure 2).2 Case Reports in Medicine
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Figure 1: Images of the left eye at presentation. (a) Fluorescein angiography shows multiple, punctate, hyperﬂuorescent RPE changes and
optic nerve hyperﬂuorescence. (b) Optical coherence tomography shows subretinal ﬂuid in the macula.
(a) (b)
Figure 2: Images of the left eye after a 5-month loss to follow-up (the visual acuity was ﬁnger counting). (a) Fluorescein angiography shows
an active CNVM. (b) Optical coherence tomography shows a parafoveal CNVM and mild intraretinal ﬂuid.
(a) (b)
(c)
Figure 3: Images of the left eye 12 months after the third ranibizumab injection. (a) Color fundus photo shows retinal hemorrhage
surrounding a CNVM, hyperpigmented macular RPE, and peripheral RPE hypopigmentation. (b) Fluorescein angiography shows a CNVM
and hyperﬂuorescent, peripheral RPE changes. (c) Optical coherence tomography shows a parafoveal CNVM with a signiﬁcantly increased
amount of intraretinal ﬂuid (compare with Figure 2(b)).Case Reports in Medicine 3
MTX treatment was reestablished. Following 3 intravitreal
ranibizumab injections 6 weeks apart, vision improved to
20/40 in the left eye. Twelve months after the third injection,
although the inﬂammation was controlled with MTX, vision
in the left eye had again decreased to CF due to subretinal
hemorrhage, increased amount of intraretinal ﬂuid, and a
recurrent CNVM (Figure 3). This was treated with a fourth
intravitreal injection of ranibizumab. However, neither
vision nor the CNVM showed improvement. The patient
was ambivalent about receiving subsequent injections, and
with a centrally located macular scar, the expected visual
outcome was extremely poor. At last followup, 20 months
after the fourth injection, vision in the left eye was 20/400
with pinhole and an inactive CNVM with RPE hypertrophy
was noted. Visual acuity in the fellow eye was 20/30.
3. Discussion
VKH may be complicated by the development of treatment-
refractive CNVMs, which prognosticate a poor visual out-
come [4]. Vascular endothelial growth factor (VEGF) is a
key inducer of neovascularization [5]. Thus, ranibizumab,
an anti-VEGF antibody, is a rational modality for managing
CNVM formation. Anti-VEGF compounds have shown to
be eﬀective against idiopathic choroidal neovascularization
(CNV) and CNV secondary to myopia, uveitis, angioid
streaks, central serous chorioretinopathy, and punctate inner
choroidopathy [6–9]. More speciﬁcally, Wu and colleagues
[10] successfully treated 2 cases of CNV secondary to
VKH with intravitreal injections of bevacizumab. Some
additional treatment options that warrant investigation in
the management of VKH-associated CNVMs include photo-
dynamictherapy,laserphotocoagulation,andcombinational
pharmacotherapy of anti-VEGF compounds with immuno-
suppressants. For example, in a study of subfoveal CNV in
6 VKH patients, Nowilaty et al. [11] showed that treatment
with PDT with verteporﬁn was safe and eﬀective. While
Soheilian and coworkers [12] demonstrated that addition of
MTX to bevacizumab in the treatment of CNV secondary
to age-related macular degeneration may enhance CNV
regressionanddecreasescartissueformationbyanunknown
mechanism.
In our patient, intravitreal ranibizumab initially led to
CNVM regression as well as improvement and stabiliza-
tion of vision. However, even in the absence of apparent
inﬂammation, the CNVM recurred and became refractory
to ranibizumab. Despite the fact that inﬂammation and
neovascularization can be managed with immunomodu-
lators, such as corticosteroids and MTX, and anti-VEGF
compounds, the chronicity of this disease may lead to
permanent loss of vision. In patients with VKH complicated
by CNVM, prospective studies should be carried out to
determine whether prolonged anti-VEGF therapy, alone or
in combination with other treatment modalities, should be
considered to reduce recurrent membrane formation, even
in the absence of ocular inﬂammation.
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